Completed PHASE1 INTERVENTIONAL 1-arm NCT01132625

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies

Sponsor: Novartis Pharmaceuticals

Conditions Advanced Solid Tumors

Interventions AUY922

Updated 5 times since 2017 Last updated: Dec 6, 2020 Started: Nov 30, 2008 Primary completion: May 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01132625, this PHASE1 trial focuses on Advanced Solid Tumors and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kashiwa, Japan
• Sunto-gun, Japan